List of Figures
Figure 1: Ophthalmology Therapeutics, Global, Innovation Trends in Product Approvals, Number of Product Approvals by FDA and Five-Year Moving Average of Products Approvals (%), 1987–2012 6
Figure 2: Ophthalmology Therapeutics, Global, First-in-Class and Non-First-in-Class Products, Sales Performance After Marketing Approval ($m) 8
Figure 3: Ophthalmology Therapeutics, Global, Overview of Marketed Products, 2017 22
Figure 4: Ophthalmology Therapeutics, Global, Overview of Pipeline Products, 2017 23
Figure 5: Ophthalmology Therapeutics, Global, Pipeline by Stage of Development and Molecule Type, 2017 24
Figure 6: Ophthalmology Therapeutics, Global, Pipeline by Key Indications and Stage of Development, 2017 25
Figure 7: Ophthalmology Therapeutics, Global, Pipeline by Key Indications and Molecule Type, 2017 26
Figure 8: Ophthalmology Therapeutics, Global, Pipeline by Molecular Target, 2017 27
Figure 9: Ophthalmology Therapeutics, Global, Pipeline by Key Indications and Molecular Target, 2017 28
Figure 10: Ophthalmology Therapeutics, Global, Molecular Target Family Comparison, Pipeline and Marketed Products, 2017 28
Figure 11: Ophthalmology Therapeutics, Global, Molecular Target Family Comparison, Pipeline First-in-Class and Established Molecular Targets, 2017 29
Figure 12: Ophthalmology Therapeutics, Global, Percentage of First-in-Class Products in Pipeline by Stage of Development (%), 2017 30
Figure 13: Ophthalmology Therapeutics, Global, Percentage of First-in-Class Products in Pipeline by Molecular Target Family (%), 2017 30
Figure 14: Ophthalmology Therapeutics, Global, Ratio of First-in-Class Products to First-in-Class Targets by Stage of Development, 2017 30
Figure 15: Ophthalmology Therapeutics, Global, Percentage of First-in-Class Products in Pipeline by Stage of Development (%), 2017 31
Figure 16: Ophthalmology Therapeutics, Global, First-in-Class Products in Pipeline (Part 1), 2017 31
Figure 17: Ophthalmology Therapeutics, Global, First-in-Class Products in Pipeline (Part 2), 2017 32
Figure 18: Ophthalmology Therapeutics, Global, First-in-Class Products in Pipeline (Part 3), 2017 32
Figure 19: Ophthalmology Therapeutics, Global, First-in-Class Products in Pipeline (Part 4), 2017 33
Figure 20: Ophthalmology Therapeutics, Global, First-in-Class Products in Pipeline (Part 5), 2017 33
Figure 21: Ophthalmology Therapeutics, Global, First-in-Class Products in Pipeline (Part 6), 2017 34
Figure 22: Ophthalmology Therapeutics, Global, First-in-Class Products in Pipeline (Part 7), 2017 35
Figure 23: Ophthalmology Therapeutics, Global, First-in-Class Products in Pipeline (Part 8), 2017 35
Figure 24: Ophthalmology Therapeutics, Global, First-in-Class Products in Pipeline (Part 9), 2017 36
Figure 25: Ophthalmology Therapeutics, Global, First-in-Class Products in Pipeline (Part 10), 2017 36
Figure 26: Ophthalmology Therapeutics, Global, First-in-Class Products in Pipeline (Part 11), 2017 37
Figure 27: Ophthalmology Therapeutics, Global, First-in-Class Products in Pipeline (Part 12), 2017 38
Figure 28: Ophthalmology Therapeutics, Global, First-in-Class Products in Pipeline (Part 13), 2017 39
Figure 29: Ophthalmology Therapeutics, Global, Target Matrix Assessment (Part 1), 2017 42
Figure 30: Ophthalmology Therapeutics, Global, Target Matrix Assessment (Part 2), 2017 43
Figure 31: Ophthalmology Therapeutics, Global, Target Matrix Assessment (Part 3), 2017 44
Figure 32: Ophthalmology Therapeutics, Global, Pipeline Programs Targeting XXX, 2017 46
Figure 33: Ophthalmology Therapeutics, Global, Pipeline Programs Targeting XXX, 2017 47
Figure 34: Ophthalmology Therapeutics, Global, Pipeline Programs Targeting XXX, 2017 48
Figure 35: Ophthalmology Therapeutics, Global, Pipeline Programs Targeting XXX, 2017 48
Figure 36: Ophthalmology Therapeutics, Global, Pipeline Programs Targeting XXX, 2017 50
Figure 37: Ophthalmology Therapeutics, Global, Pipeline Programs Targeting XXX, 2017 52
Figure 38: Ophthalmology Therapeutics, Global, Pipeline Programs Targeting XXX, 2017 52
Figure 39: Pharmaceutical Industry, Global, Licensing Deals by Stage of Development, 2006–2015 53
Figure 40: Pharmaceutical Industry, Global, Licensing Deal Values by Stage of Development ($m), 2006–2014 54
Figure 41: Ophthalmology Therapeutics, Global, Licensing Deals, 2006–2017 55
Figure 42: Ophthalmology Therapeutics, Global, Licensing Deals by Indication and Value, 2006–2017 56
Figure 43: Ophthalmology Therapeutics, Global, Licensing Deals by Stage of Development, Deal Value and Upfront Payment Value, 2006–2017 56
Figure 44: Ophthalmology Therapeutics, Global, Licensing Deals by Molecule Type and Mechanism of Action, 2006–2017 57
Figure 45: Ophthalmology Therapeutics, Global, Licensing Deals Valued Above $100m 58
Figure 46: Ophthalmology Therapeutics, Global, Co-development Deals, 2006–2017 59
Figure 47: Ophthalmology Therapeutics, Global, Co-development Deals by Indication and Value, 2006–2017 59
Figure 48: Ophthalmology Therapeutics, Global, Co-development Deals by Stage of Development, Deal Value and Upfront Payment Value, 2006–2017 60
Figure 49: Ophthalmology Therapeutics, Global, Co-development Deals by Molecule Type and Mechanism of Action, 2006–2017 61
Figure 50: Ophthalmology Therapeutics, Global, Licensing Deals Valued Above $100m 61
Figure 51: Ophthalmology Therapeutics, Global, First-in-Class Therapies Involved in Previous Deals, 2017 62
Figure 52: Ophthalmology Therapeutics, Global, First-in-Class Therapies Not Involved in Previous Deals (Part 1), 2017 63
Figure 53: Ophthalmology Therapeutics, Global, First-in-Class Therapies Not Involved in Previous Deals (Part 2), 2017 64